-
The Israel Medical Association Journal... Dec 2020
Topics: Endoscopy; Humans; Minimally Invasive Surgical Procedures; Orbit; Orbital Neoplasms; Visual Acuity
PubMed: 33381956
DOI: No ID Found -
The Canadian Veterinary Journal = La... Jan 2021A 12-year-old castrated male cocker spaniel dog was presented with a 4-week history of left episcleral injection and pawing at the face. Clinical examination findings...
A 12-year-old castrated male cocker spaniel dog was presented with a 4-week history of left episcleral injection and pawing at the face. Clinical examination findings included left internal and external ophthalmoplegia, left dorsal strabismus, pain opening the mouth, and intermittent amaurosis. Imaging studies revealed a left orbital apex mass with adjacent sphenoid bone lysis and extension into the cranial cavity. A left exenteration was performed and histopathology confirmed an orbital soft tissue sarcoma. Key clinical message: This report describes an orbital tumor causing orbital apex syndrome. This condition should be differentiated from cavernous sinus syndrome as the latter does not course with optic neuropathy.
Topics: Animals; Dog Diseases; Dogs; Male; Ophthalmoplegia; Orbital Diseases; Orbital Neoplasms; Sarcoma; Syndrome
PubMed: 33390595
DOI: No ID Found -
Eye (London, England) Mar 2018PurposeThe purpose of this study is to discuss the clinical presentation, management, and outcomes of patients with primary orbital Ewing sarcoma family of tumors...
PurposeThe purpose of this study is to discuss the clinical presentation, management, and outcomes of patients with primary orbital Ewing sarcoma family of tumors (ESFTs).Patients and methodsRetrospective study of 12 patients with biopsy-proven primary orbital ESFT.ResultsThe mean age at presentation of primary orbital ESFT was 12 years (median, 8 years; range, 5 months to 28 years). There were seven (58%) females and five (42%) males. The presenting complaints included proptosis (n=10; 83%) and swelling in the upper eyelid (n=2; 17%). The mean duration of symptoms was 9 weeks (median, 5 weeks; range, 2-24 weeks). Tumor epicenter was located in the superior orbit (n=6; 50%), lateral orbit (n=3; 25%), inferior orbit (n=2; 17%), and medial orbit (n=1; 8%). Computed tomography of the orbits revealed predominant bony lesion (n=10; 83%) or isolated soft tissue/extraosseous lesion (n=2, 17%). At presentation, extraorbital extension was noticed in 10 patients including intra cranial extension (n=7; 58%), extension into temporal fossa (n=4; 33%), nasal cavity (n=2; 17%), maxillary sinus (n=2; 17%), and ethmoid sinus (n=1, 8%). Systemic metastases at presentation was detected in five (42%) patients involving the bone marrow (n=4; 33%), kidney (n=1; 8%), and retroperitoneal lymphnode (n=1; 8%). Multi-modal treatment including a combination of neoadjuvant chemotherapy, excision biopsy/debulking, and/or radiotherapy was given. Over a mean follow-up period of 21 months (median, 7 months; range, 1-152 months), disease-related death occurred in 11 (92%) cases.ConclusionPrimary orbital ESFT is aggressive at presentation and is associated with poor prognosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Male; Orbital Neoplasms; Prognosis; Retrospective Studies; Sarcoma, Ewing; Tomography, X-Ray Computed; Young Adult
PubMed: 29219959
DOI: 10.1038/eye.2017.278 -
Indian Journal of Ophthalmology Sep 2016Primary extraskeletal osteosarcoma (EOS) is an extremely rare malignancy. In this report, the clinical course of a 32-year-old man presenting with proptoses is... (Review)
Review
Primary extraskeletal osteosarcoma (EOS) is an extremely rare malignancy. In this report, the clinical course of a 32-year-old man presenting with proptoses is described. Medical history included Hirschsprung disease (HD), horseshoe kidney, azoospermia, and vertebral anomalies. Imaging of the orbit showed an oval, well-defined heterogeneous mass adjacent to the lateral wall of the orbit. The patient underwent a lateral orbitotomy and complete excision of the mass. The mass was not attached to the bone. Histopathologic and immunohistochemical examination confirmed the diagnosis of an EOS. The patient received chemotherapy and radiotherapy and is free of the disease 3 years after the diagnosis. Genetic screening showed no mutations for both the RET proto-oncogene for HD and the p53 tumor suppressor gene for osteosarcoma.
Topics: Adult; Exophthalmos; Humans; Magnetic Resonance Imaging; Male; Ophthalmologic Surgical Procedures; Orbital Neoplasms; Osteosarcoma; Proto-Oncogene Mas; Tomography, X-Ray Computed; Visual Acuity
PubMed: 27853024
DOI: 10.4103/0301-4738.97555 -
Acta Ophthalmologica Jun 2009We aimed to report a case of orbital solitary fibrous tumour (SFT) in a child and to review the relevant literature. (Review)
Review
PURPOSE
We aimed to report a case of orbital solitary fibrous tumour (SFT) in a child and to review the relevant literature.
METHODS
We describe an SFT in a 13-year-old boy with a 1-month history of painless proptosis in the left eye.
RESULTS
Magnetic resonance imaging revealed a well circumscribed mass filling most of the left intraconal orbit. The lesion was excised and histopathological examination revealed a malignant SFT. Postoperative follow-up for 18 months was uneventful.
CONCLUSIONS
Malignant SFT of the orbit should be included in the differential diagnosis of paediatric orbital tumours. Complete surgical excision remains the preferred method of management and the longterm prognosis is guarded.
Topics: Adolescent; Diagnosis, Differential; Eye; Hemangiopericytoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Orbital Neoplasms; Solitary Fibrous Tumors; Tomography, X-Ray Computed
PubMed: 18823286
DOI: 10.1111/j.1755-3768.2008.01290.x -
Radiation Oncology (London, England) Dec 2009Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital tumors. Radiotherapy on the orbital cavity is the treatment of choice for this unusual...
BACKGROUND
Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital tumors. Radiotherapy on the orbital cavity is the treatment of choice for this unusual presentation of localized non-Hodgkin's lymphoma (NHL). The aim of this study is to retrospectively evaluate the effectiveness and the toxicity of radiation treatment in patients with primary orbital lymphoma.
METHODS
Forty-seven consecutive patients having primary orbital lymphoma treated in our department between May 1983 and September 2006 were investigated in a retrospective study. Either 60Co gamma rays or 6 MV X rays were used to deliver daily fractions of 1.8 or 2.0 Gy, 5 times/week, with total doses ranging from 34.2 to 50 Gy. Forty-three patients had stage IE, three had stage II and one stage IV disease. Thirty-eight patients had marginal zone B-cell lymphoma, 5 diffuse large B cell lymphoma, 3 mantle cell lymphoma and 1 Burkitt lymphoma. Local control (LC), disease free survival (DFS), overall survival (OS) and late side effects were evaluated in all patients.
RESULTS
With a median follow up of 45 months, LC was obtained in 100% of patients. The estimated 5- and 7-year DFS rates were 75.8% and 55.3%, and the 5- and 7-year OS rates were 88.7% and 79.9% respectively. Acute toxicity was minimal. Late toxicity such as cataract, keratitis, retinopathy and xerophthalmia occurred respectively in 12 (25.5%), 5 (10.6%), 1 (2.1%), and 9 (19.1%) patients.
CONCLUSION
Radiotherapy is an effective and at the same time well tolerated treatment for primary orbital lymphoma.
Topics: Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Orbital Neoplasms; Radiotherapy; Retrospective Studies; Treatment Outcome
PubMed: 19968864
DOI: 10.1186/1748-717X-4-60 -
The British Journal of Ophthalmology Sep 1989We describe three patients with malignant peripheral nerve tumours in the orbit and review the existing literature on these rare lesions. (Review)
Review
We describe three patients with malignant peripheral nerve tumours in the orbit and review the existing literature on these rare lesions.
Topics: Adult; Humans; Male; Middle Aged; Neurofibroma; Orbital Neoplasms; Peripheral Nervous System Neoplasms
PubMed: 2679875
DOI: 10.1136/bjo.73.9.731 -
Ocular Immunology and Inflammation Jun 2010To describe a case of orbital mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as unilateral panuveitis.
PURPOSE
To describe a case of orbital mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as unilateral panuveitis.
METHODS
Retrospective chart review.
RESULTS
A 53-year-old female patient with unilateral vitritis and exudative retinal detachment refractory to immunosuppressive treatment was eventually diagnosed with orbital MALT lymphoma. Following treatment with radiotherapy and rituximab, the patient's intraocular inflammation and retinal detachment resolved.
CONCLUSIONS
Orbital MALT lymphoma can masquerade as refractory unilateral panuveitis with exudative retinal detachment and appears to respond to a combination of radiotherapy and specific B-cell-targeted systemic therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Diagnosis, Differential; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Orbital Neoplasms; Panuveitis; Radiotherapy, Adjuvant; Rituximab; Tomography, Optical Coherence; Tomography, X-Ray Computed
PubMed: 20482392
DOI: 10.3109/09273941003728947 -
AJNR. American Journal of Neuroradiology 1992
Review
Topics: Eye Abnormalities; Glaucoma; Humans; Infant, Newborn; Lacrimal Duct Obstruction; Magnetic Resonance Imaging; Orbital Neoplasms; Teratoma; Tomography, X-Ray Computed
PubMed: 1566729
DOI: No ID Found -
JAMA Ophthalmology Dec 2017To our knowledge, the clinical features of ocular adnexal mantle-cell lymphoma (OA-MCL) have not previously been evaluated in a large multicenter cohort.
IMPORTANCE
To our knowledge, the clinical features of ocular adnexal mantle-cell lymphoma (OA-MCL) have not previously been evaluated in a large multicenter cohort.
OBJECTIVE
To characterize the clinical features of OA-MCL.
DESIGN, SETTING, AND PARTICIPANTS
This retrospective multicenter study included patient data collected from January 1, 1980, through December 31, 2015, at 6 eye cancer centers in 4 countries. Medical records of 55 patients with OA-MCL were reviewed; the median length of follow-up was 33 months.
MAIN OUTCOMES AND MEASURES
Overall survival, disease-specific survival, and progression-free survival were the primary end points.
RESULTS
Fifty-five patients were included; ocular adnexal MCL was found to be most common in older individuals (mean age, 70 years) and men (n = 42 of 55; 76%). Patients with OA-MCL frequently presented with disseminated lymphoma (n = 34 of 55; 62%), and were likely to experience stage IVE disease (n = 35 of 55; 64%), with bilateral involvement (n = 27 of 55; 47%), tumor masses (n = 27 of 36; 75%), and involvement of the orbit (n = 32 of 55; 58%). Chemotherapy with or without external beam radiation therapy was the most frequently used treatment. Overall survival rates for the entire cohort were 65% at 3 years (95% CI, 52%-78%) and 34% at 5 years (95% CI, 21%-47%). Disease-specific survival after 5 years was 38% for the entire cohort (95% CI, 25%-51%); the disease-specific survival adjusted by eye cancer center was better in patients who had received rituximab in addition to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.7; P = .06). The median progression-free survival was 2.3 years (95% CI, 1.8-2.7 years) in patients who experienced recurrence after primary treatment, and 4.1 years (95% CI, 3.9-4.3 years) in patients who presented with a relapse of systemic lymphoma in the ocular adnexal region.
CONCLUSIONS AND RELEVANCE
These results suggest that the distinctive features of OA-MCL are its appearance in older male individuals, advanced stage and bilateral manifestation at the time of diagnosis, and aggressive course. The prognosis of patients with OA-MCL might be improved by addition of rituximab to chemotherapy treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cohort Studies; Combined Modality Therapy; Conjunctival Neoplasms; Disease-Free Survival; Eye Neoplasms; Eyelid Neoplasms; Female; Humans; Lacrimal Apparatus Diseases; Lymphatic Metastasis; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Retrospective Studies; Survival Rate
PubMed: 29121219
DOI: 10.1001/jamaophthalmol.2017.4810